Finerenone

Finerenone, also known as BAY 94-8862, serves as a mineralocorticoid receptor antagonist that is prescribed to lessen the likelihood of a sustained decrease in glomerular filtration rate, end-stage kidney disease, cardiovascular mortality, myocardial infarctions, and hospitalization resulting from heart failure in individuals with chronic kidney disease linked to type II diabetes. Initially, patients with kidney ailments would typically receive spironolactone or eplerenone to counteract the mineralocorticoid receptor. While spironolactone exhibits minimal selectivity and affinity towards the receptor, swiftly detaching and potentially impacting the androgen, progesterone, and glucocorticoid receptors, eplerenone displays greater selectivity and prolonged effects. Subsequent advancements introduced more selective nonsteroidal mineralocorticoid antagonists like apararenone, esaxerenone, and finerenone. To date, finerenone remains the sole nonsteroidal mineralocorticoid receptor antagonist approved by the FDA.